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Recurrent pregnancy loss, defi ned as two or 
more spontaneous abortions, aff ects 5% of 
all women of reproductive age. Epidemiologi-
cal studies suggest that inherited and acquired 
thrombophilia of the mother, such as that 
caused by the Leiden polymorphism in blood 
coagulation factor V, contributes to the patho-
genesis of fetal loss, as well as other adverse 
pregnancy outcomes (1–3). These studies also 
demonstrate a high study-to-study variability 
of association strength, suggesting the existence 
of as yet uncharacterized risk modifi ers. The 
pathogenesis of thrombophilia-associated fetal 
loss remains to be established. Evaluation of 
placental pathologies has not revealed a clear 
correlation between the prothrombotic status 
of the mother and the presence of villous in-
farcts, blood clots, or fi brin deposits in the pla-
centa (4, 5), raising the question of whether 
thrombotic processes are indeed causative in 
thrombophilia-associated fetal loss or constitute 
an epiphenomenon. On the other hand, clinical 
trials suggest that heparin anticoagulation may 
indeed mitigate pregnancy failure in prothrom-
botic women (6–9). In view of the uncertain 
etiology of thrombophilia-associated preg-
nancy failure and the lack of established criteria 
for a more precise risk stratifi cation enabling 
identifi cation of truly at-risk pregnancies, the 
prophylactic anticoagulation of asymptomatic 
women and the risk-to-benefi t balance of anti-
coagulation therapy during pregnancy are sub-
jects of intense debate (10–12).
Factor V Leiden (FvL) polymorphism, which 
renders coagulation factor V refractory to inacti-
vating proteolysis by activated protein C, has 
been associated with both early (fi rst trimester) 
and late fetal loss in women (2). In experimental 
mouse models homozygous status for the FvL 
polymorphism elicits pronounced thrombo-
philia but is not associated with intrauterine fetal 
loss or impaired fecundity (13). In contrast, ob-
servations in animals lacking the receptor com-
ponents of the protein C anticoagulant pathway, 
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We describe a mouse model of fetal loss in factor V Leiden (FvL) mothers in which fetal 
loss is triggered when the maternal prothrombotic state coincides with fetal gene defects 
that reduce activation of the protein C anticoagulant pathway within the placenta. Fetal 
loss is caused by disruption of placental morphogenesis at the stage of labyrinth layer 
formation and occurs in the absence of overt placental thrombosis, infarction, or perfusion 
defects. Platelet depletion or elimination of protease-activated receptor 4 (Par4) from the 
mother allows normal placentation and prevents fetal loss. These fi ndings establish a 
cause–effect relationship for the observed epidemiologic association between maternal FvL 
status and fetal loss and identify fetal gene defects as risk modifi ers of pregnancy failure 
in prothrombotic mothers. Pregnancy failure is mediated by Par4-dependent activation of 
maternal platelets at the fetomaternal interface and likely involves a pathogenic pathway 
independent of occlusive thrombosis. Our results further demonstrate that the interaction 
of two given thrombosis risk factors produces markedly disparate consequences on disease 
manifestation (i.e., thrombosis or pregnancy loss), depending on the vascular bed in which 
this interaction occurs.
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thrombomodulin (Thbd) and the endothelial protein C re-
ceptor (Procr), demonstrate that the integrity of this path-
way within the placenta is essential for the maintenance of 
pregnancy (14–16). Thbd- or Procr-knockout mice die in 
utero because of a placental malfunction that results from a 
lack of these receptors on zygote-derived trophoblast cells 
that line the passage of maternal circulation in the placenta. 
Importantly, fetal loss in these animal models occurs in the 
absence of maternal thrombophilia, and the relevance of 
these knockout models for fetal loss in thrombophilic moth-
ers remains unclear.
In this paper, we test the hypothesis that the hemostatic 
balance in the placental vasculature is determined by the com-
bination of maternal and fetal factors, which cooperatively 
regulate the activity of the coagulation system at the interface 
of maternal blood and fetal trophoblasts. We test and demon-
strate this eff ect in a mouse model of pregnancy disorder in 
FvL mothers in which fetal loss is triggered by a combination 
of maternal and fetal prothrombotic defects. We exploit this 
model to identify risk modifi ers of fetal loss associated with 
maternal FvL status and to characterize the pathogenic mech-
anism underlying pregnancy failure.
RESULTS
Development of an animal model of fetal loss associated 
with maternal thrombophilia
Two genetically altered strains of mice were used: mice with 
APC resistance caused by the FvL polymorphism (13) and 
Thbd Pro mice with a reduced ability to activate protein C 
zymogen (17). Both strains are viable in the homozygous 
state for the mutated allele and exhibit biochemical evidence 
of chronic, low-grade thrombin generation leading to en-
hanced fi brin deposition in multiple tissues but do not de-
velop spontaneous thrombosis on a C57BL/6 genetic 
background. Homozygous FvQQ and ThbdProPro mice exhibit 
normal fertility and fecundity (13, 17). These two strains of 
mice were intercrossed to produce FvQQThbdPro+ females in 
which we could assess pregnancy outcome as a function of 
Thbd expression on fetal trophoblast cells.
Off spring of FvQQThbdPro+ intercrosses showed a com-
plete absence of FvQQThbdProPro animals and a signifi cant 
 underrepresentation of FvQQTMPro+ pups (Table I, row 1). 
FvQQThbdPro+ females mated to ThbdProPro males, likewise, 
did not support intrauterine development of FvQ+ThbdProPro 
embryos (Table I, row 2). In contrast, in the reverse genetic 
cross (i.e., ThbdProPro females mated with FvQQThbdPro+ 
males; Table I, row 3), viable FvQ+ThbdProPro pups were born 
(P = 0.009 compared with FvQQThbdPro+ females mated to 
ThbdProPro males). Thus, FvQQThbdPro+ females do not sup-
port uterine development of FvQ+ThbdProPro embryos. Of 
note, viable FvQQThbdProPro off spring were obtained from in-
tercrosses of FvQ+ThbdProPro animals (Table I, row 4), show-
ing that compound homozygosity of FvL and TMPro alleles in 
the embryo is compatible with normal development. The 
compound homozygous animals did not develop thrombosis 
over a 1-yr observation period.
Although the data in the previous paragraph clearly dem-
onstrates that ThbdProPro embryos are aborted in FvQQThb-
dPro+ females but can survive in ThbdProPro females, we noted 
partial fetal loss of ThbdProPro embryos in the latter, which is 
refl ected in a lower frequency of this genotype than predicted 
by Mendelian inheritance (P = 0.003; Table I, row 3). Partial 
loss of ThbdProPro embryos was also observed when the 
ThbdProPro females were mated to ThbdPro/+ males (Table I, 
compare rows 5 and 6), demonstrating synergy between fetal 
and maternal Thbd defi ciency in mediating fetal loss. To 
unequivocally demonstrate the eff ect of maternal FvL status 
on fetal loss in the absence of the ThbdPro mutation in the 
mother, we assessed the survival of ThbdPro+ embryos in 
FvQQ mothers with normal Thbd expression. Signifi cantly 
reduced numbers of FvQ+ThbdPro+ mice were observed in 
the off spring of FvQQ females mated with ThbdPro+ males 
(Table I, row 7), demonstrating the loss of ThbdPro+ embryos 
in FvQQ mothers.
These results show that (a) fetal loss occurs in female mice 
with a latent prothrombotic state caused by homozygous sta-
tus for either the FvQ or the ThbdPro allele; (b) the penetrance 
of fetal loss phenotype in these prothrombotic mothers is in-
creased by reduced fetal Thbd function; and (c) the combina-
tion of the same risk factors within vascular compartments 
other than the placenta is compatible with normal develop-
ment and hemostasis.
Table I. Pregnancy outcome in FvL mothers
Parental genotype Genotype of offspring
Female Male Fv
++ 
ThbdPro+
Fv++ 
ThbdProPro
FvQ+ 
Thbd++
FvQ+ 
ThbdPro+
FvQ+ 
ThbdProPro
FvQQ 
Thbd++
FvQQ 
ThbdPro+
FvQQ 
ThbdProPro
n
FvQQ ThbdPro+ FvQQ ThbdPro+ – – – – – 27 19* 0* 46
FvQQ ThbdPro+ Fv++ ThbdProPro – – – 15 0* – – – 15
Fv++ ThbdProPro FvQQ ThbdPro+ – – – 22 10** – – – 32
FvQ+ ThbdProPro FvQ+ ThbdProPro – 12 – – 30 – – 9 51
Fv++ ThbdProPro Fv++ ThbdPro+ 15 4** – – – – – – 19
Fv++ ThbdPro+ Fv++ ThbdProPro 14 12 – – – – – – 26
FvQQ Thbd++ Fv++ ThbdPro+ – – 41 22# – – – – 63
p-values were calculated by χ2 analysis using the expected numbers based on Mendelian inheritance. *, P < 0.0003; **, P < 0.04; #, P < 0.02. n, total number of pups analyzed.
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Disparate consequences of thrombosis risk factor 
interactions in the placenta and nonplacental vascular beds
To extend our fi ndings on Thbd function in pregnancy to 
additional, putative risk modifi ers of fetal loss, we investi-
gated how reduced tissue factor pathway inhibitor (Tfpi) and 
Procr function on fetal trophoblast cells aff ect pregnancy 
outcomes in FvL mothers. Genetic suppression of tissue factor–
mediated procoagulant activity expressed by trophoblast cells 
prevents the intrauterine loss of Thbd−/−, as well as Procr−/− 
embryos, suggesting that the level of tissue factor inhibition 
by Tfpi on trophoblast cells may be a critical modulator of 
the risk of fetal loss in prothrombotic mothers (15, 16). The 
combination of heterozygous Tfpi defi ciency with homo-
zygous carrier status for the FvL mutation in the systemic 
vasculature causes fatal thrombosis shortly after birth in 
FvQQTfpi+/− animals (18).
An analysis of crosses between Tfpi+/− males and FvQQ 
females showed a trend of reduced survival of Tfpi+/− em-
bryos in FvQQ mothers (62 FvQ+ Tfpi+/− vs. 80 FvQ+ Tfpi+/+), 
but the skewing of genotype distribution did not reach sta-
tistical signifi cance. No intrauterine loss of Tfpi+/− embryos 
was observed in FvQQThbdPro+ mothers mated to Tfpi+/− 
males (5 FvQ+Thbd+/+Tfpi+/+, 6 FvQ+ThbdPro/+Tfpi+/+, 
7 FvQ+Thbd+/+Tfpi+/−, and 3 FvQ+ThbdPro/+Tfpi+/−; n = 21). 
In conclusion, reduced Tfpi expression at the blood–
trophoblast interface within the placental vascular bed does 
not signifi cantly increase the risk of pregnancy failure in 
FvL mothers.
Procr, like Tfpi, is coexpressed with Thbd by fetal tropho-
blast cells (19) and facilitates Thbd-mediated activation of pro-
tein C. To examine whether reduced Procr expression by 
trophoblast cells causes pregnancy failure in FvL mothers, we 
used “low Procr” mice (i.e., homozygous Procrδδ). These mice 
exhibit severely reduced Procr expression yet develop and re-
produce normally (20). FvQ+Procrδδ pups were signifi cantly 
underrepresented in the off spring of FvQQProcrδ+ females 
mated to Procrδδ males (5 FvQ+Procrδδ vs. 18 FvQ+Procrδ+; n = 
23; P < 0.007). In contrast, intercrosses of FvQ+Procrδδ mice 
yielded normal frequencies of FvQ+Procrδδ and FvQQProcrδδ 
pups (12 FvQ+Procrδδ, 5 FvQQProcrδδ, and 4 Fv++Procrδδ; n = 
21), which remained completely viable and normal as adults. 
Therefore, akin to the ThbdPro mutation, reduced fetal Procr 
expression increases the risk of pregnancy failure in homozy-
gous FvL mothers, whereas the same interaction does not pro-
duce a thrombotic pathology within the systemic vasculature.
Placental pathology of pregnancy failure in FvL females
Progeny from FvQQThbdPro+ intercrosses were analyzed at 
E10.5, E12.5, and E17.5 to determine the time of pregnancy 
Figure 1. Phenotype of ThbdProPro embryos in FVQQThbdPro+ 
mothers. (a, c, and e) ThbdPro+ littermates at E9.5, E12.5, and E18.5, 
respectively, of ThbdProPro embryos (b, d, and f). At E9.5, some ThbdProPro 
embryos are smaller (b). By E11.5, most ThbdProPro embryos are in an 
 advanced stage of decay (d). Platelet depletion of the mother with anti-
GP1bα antibody treatment (e and f) results in normal-appearing ThbdProPro 
embryos. Pictures were taken at different magnifi cations. Bars, 1 mm.
Table II. Intrauterine survival of ThbdProPro embryos in FvQQThbdPro+ mothers
Breeding pairs Genotype of embryos
Female Male Stage of embryonic 
development
FvQQ 
Thbd++
FvQQ 
ThbdPro+
FvQQ 
ThbdProPro
FvQ+ 
ThbdPro+
FvQ+ 
ThbdProPro
n
FvQQ ThbdPro+   FvQQ ThbdPro+
      E10.5 10 23 2* – – 35
      E12.5 18 13* 1* – – 32
      E17.5  9 11 0* – – 20
FvQQ ThbdPro+   Fv++ ThbdProPro
      E9.5 – – –  5 7 12
      E11.5 – – – 12 0* 12
p-values were calculated by χ2 analysis using the expected numbers based on Mendelian inheritance. *, P < 0.004. Embryos in advanced stages of degradation were excluded 
from the analysis. n, total number of pups analyzed.
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failure and the associated pathology of FvQQThbdProPro embryos 
(Table II). Seven out of nine FvQQThbdProPro embryos were 
resorbed or severely developmentally retarded by E10.5; only 
one ThbdProPro embryo was present at E12.5, and none were 
at E17.5 (Table II). In timed pregnancies of FvQQThbdPro+ 
females mated to ThbdProPro males (Table II), FvQ+ThbdProPro 
embryos were present in normal numbers at E9.5, but some 
of these were already smaller or delayed in developmen-
tal progress at this time (Fig. 1, a and b). By E11.5, all 
FvQ+ThbdProPro embryos were in a stage of advanced decay 
(Fig. 1, c and d). These fi ndings indicate that, in FvQQThb-
dPro+ mothers, ThbdProPro embryos exhibit growth defects as 
early as E9.5 and that fetal loss is observed as early as E10.5. 
Although some embryos appear normal at this time, even-
tually all ThbdProPro embryos in FvQQThbdPro+ mothers are 
eliminated before birth, and this occurs irrespective of the 
FvL status (homozygous or heterozygous) of the embryo. In 
contrast to ThbdProPro embryos, ThbdPro+ embryos are pre-
sent in normal numbers and appearance at E10.5 but are 
under-represented at E12.5.
At E9.5, uteroplacental units corresponding to 
FvQ+ThbdProPro embryos tended to be smaller in comparison 
with littermate controls. Morphometric analysis of histologi-
cal sections through these units showed a signifi cantly higher 
decidual/placental ratio in units corresponding to apparently 
normal ThbdProPro embryos compared with ThbdPro+ and 
Thbd+/+ littermates, and this diff erence was more pro-
nounced in units corresponding to retarded ThbdProPro em-
bryos (Fig. 2 and Fig. 3, a and b). The smaller placental size 
could be attributed to a failure to form or expand the laby-
rinth layer of the placenta (Fig. 3, c–f). At E9.5, the placenta 
of all retarded ThbdProPro embryos (n = 8) had undergone 
chorioallantoic fusion, but the chorioallantoic surface had re-
mained fl at with little or no branching and an absence of fetal 
and maternal vessel in-growths, resulting in a distinct lack of 
a well-formed labyrinth layer. Of note, the same defect in 
labyrinth formation was also observed in three out of six pla-
centas of apparently normal ThbdProPro embryos, indicating 
that the observed placental pathology precedes embryonic 
growth retardation. The placentas of other normal-appearing 
ThbdProPro embryos had begun branching morphogenesis 
to form a labyrinth and appeared similar to placentas of 
ThbdPro+ littermates. This observation, together with the 
observed survival of occasional ThbdProPro embryos to a late 
developmental stage (E12.5), suggests that the defect may 
be in progression rather than in the initiation of chorioallan-
toic morphogenesis.
Fetal loss is not associated with placental thrombosis
Plasma levels of thrombin–antithrombin (TAT) complexes 
and D-dimer were only mildly altered in FVQQTMPro+ mice 
and were not predictive of pregnancy failure (respective values: Figure 2. Placental size of ThbdProPro embryos relative to controls. 
Each symbol represents a measurement from a single fetoplacental unit. 
All litters were analyzed at E9.5. Mean ratios and SDs are shown.
Figure 3. Placental phenotype of ThbdProPro embryos and littermate 
controls in FvQQThbdPro+ mothers. Histological sections through pla-
centas of ThbdPro+ (a, c, and e) and a phenotypically normal ThbdProPro 
(b, d, and f) embryo at E9.5. a and b show cytokeratin-expressing trophoblast 
cells (brown staining). The placenta of ThbdProPro embryos (stained area) is 
smaller than that of ThbdPro+ embryos. c and d are higher magnifi cation 
images of hematoxylin and eosin–stained sections adjacent to a and b, 
respectively. e and f correspond to boxes in c and d, respectively. Dashed 
lines in c and d mark the border of the placenta and decidua, as deter-
mined by cytokeratin staining. ThbdPro+ placentas (c and e) have formed a 
labyrinth characterized by maternal (bright red enucleated maternal red 
blood cells; dashed arrows) and fetal (purple hematoxylin-stained nucle-
ated fetal red blood cells; continuous arrow) blood spaces. The labyrinth is 
distinctly absent in the placentas of littermate ThbdProPro embryos (d and f). 
Bars, 0.1 mm.
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TAT, 4.52 ± 2.07 vs. 4.8 ± 0.92 μgapparent/l [wild type vs. 
FvQQThbdPro+; mean ± SD; P = 0.74]; D-dimer, 7.95 ± 
4.02 vs. 10.12 ± 3.47 μgapparent/l [mean ± SD; P = 0.28]). 
TAT levels of pregnant FvQQThbdPro+ animals at 9.5 days 
post coitum (dpc) were also similar to gestation stage–matched 
controls (respective values: 8.21 ± 2.44 vs. 8.46 ± 6.98 
μgapparent/l [wild type vs. FvQQThbdPro+; mean ± SD; P = 
0.95]). The numbers, sizes, location, and general appearance 
of thrombi were similar in uteroplacental units corresponding 
to Thbd++, normal ThbdProPro, and retarded ThbdProPro em-
bryos (Thbd++, 12 ± 12 clots; normal ThbdProPro, 13 ± 7 
clots; retarded ThbdProPro, 7 ± 5 clots [all mean ± SD]). 
Thrombi identifi ed by hematoxylin and eosin staining were 
validated by immunostaining with fibrin(ogen) and with 
p-selectin antibodies identifying platelet aggregates (Fig. 4). 
Spiral arteries within the deciduas were free of thrombi in 
wild-type and mutant fetoplacental units (not depicted). To 
detect blood perfusion defects secondary to potential blood 
clots in vessels not included in our survey and to rule out 
other causes of impaired blood supply to the placenta, FITC-
dextran was injected in the maternal circulation. The fl uo-
rescent tracer accumulated in the placenta of wild-type 
pregnancies in a characteristic ring-like structure formed by 
maternal blood in the labyrinth. Congruent with the devel-
opmental retardation and anatomical absence of labyrinth, 
this structure was absent in the placenta of ThbdProPro embryos 
(Fig. 5). FITC-dextran could, however, be readily visualized 
in decidual and placental blood spaces in FVQQThbdPro+ 
mothers irrespective of embryonic genotype. These data sup-
port the notion that fetal loss in the described mouse model 
cannot be attributed to occlusive thrombosis and impaired 
perfusion of the placenta.
Fetal loss in FvL mice is mediated by the protease-activated 
receptor 4 (Par4) on maternal platelets
We examined the role of platelets in the pregnancy disorder of 
FvL mothers by immunodepleting maternal platelets with 
anti-GP1bα antibodies. Platelet depletion initiated at E7.5 re-
stored normal development of ThbdProPro embryos in FvQQ 
ThbdPro+ mothers mated to ThbdProPro males (13 ThbdPro+ and 
18 ThbdProPro determined at E11.5 or later; n = 31 from four 
pregnancies). Treatment with nonimmune IgG did not pre-
vent loss of ThbdProPro embryos (9 ThbdPro+ and 1 ThbdProPro; 
Figure 4. Placental thrombosis in FvL mice. The number of placental 
thrombi was similar in placentas of wild-type and ThbdProPro embryos 
(see Results). Thrombi were identifi ed on serial sections by hematoxylin and 
eosin staining (a, c, and e), and immunostaining with antifi brinogen anti-
bodies (b) and anti–p-selectin antibodies (d and f). e and f are enlarged 
views of the boxed areas in c and d. Arrows indicate clots. Bars, 0.1 mm.
Figure 5. Assessment of decidual and placental vascular patency 
by FITC-dextran infusion. Whole-mount (a and b) and sections (c–f) of 
decidual-placental units corresponding to a wild-type embryo in a wild-
type mother (a, c, and e) and a FvQ+ThbdProPro embryo in a FvQQThbdPro+ 
mother (b, d, and f) are shown. From the fetal aspect of the placenta, a 
characteristic ring of maternal placental vasculature, marked by FITC-
dextran, is observed in wild-type pregnancies but not in placenta of a 
FvQ+ThbdProPro embryo in a FvQQThbdPro+ mother (a and b). Decidual and 
placental regions in both types of pregnancies are perfused with FITC-
dextran (c and d). Hematoxylin and eosin–stained sections adjacent to 
c and d are shown in e and f. Arrows show maternal blood spaces in the 
placenta. Bars, 1 mm.
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n = 10 from three pregnancies; P = 0.011 indicates a signifi -
cant diff erence from the numbers expected by Mendelian 
 inheritance). We observed that loss of ThbdProPro embryos 
could not be prevented when platelet depletion was initiated 
at E9.5 (17 ThbdPro+ and 2 ThbdProPro; n = 19 from four 
pregnancies; P = 0.0006 indicates a signifi cant diff erence 
from the numbers expected by Mendelian inheritance). 
These data demonstrate that maternal platelets mediate fetal 
loss of ThbdProPro mice in FvQQ ThbdPro+ mothers and sug-
gest that the initial platelet-mediated insult to the placenta 
occurs as early as E7.5.
Par4 is required for thrombin-mediated activation of 
mouse platelets. Using triallelic crosses, we generated 
FvQQPar4−/−ThbdPro+ animals to assess the role of Par4 in 
mediating pregnancy disorder. FvQQPar4−/−ThbdPro+ females 
mated with ThbdProPro males produced viable FvQ+Par4+/−
ThbdProPro term embryos (15 ThbdProPro and 15 ThbdPro+; 
n = 30) that resembled their ThbdPro+ littermates in appear-
ance and size. These data demonstrate that maternal Par4 de-
fi ciency overcomes the developmental block of ThbdProPro 
embryos in FvQQThbdPro+ mothers.
D I S C U S S I O N 
Our fi ndings reveal several new aspects of the association 
 between maternal thrombophilia and fetal loss. First, it lends 
direct experimental support to the notion that the FvL car-
rier status of the mother increases the risk of pregnancy fail-
ure, thereby establishing a cause–eff ect relationship for the 
epidemiologic association. Second, it demonstrates that he-
mostatic regulators on fetal trophoblast cells are dominant 
risk modifi ers of fetal loss in FvL carriers. Thbd and Procr, 
allelic variants of which are suspected risk modifi ers in human 
thrombophilia (21–25), are experimentally validated in the 
current mouse model as modulators of pregnancy success in 
FvL mothers. The experimental demonstration of a synergis-
tic adverse eff ect of maternal and fetal prothrombotic muta-
tions in causing pregnancy failure has direct implications for 
the risk stratifi cation of patient populations. It also validates 
the approach taken in the “NOHA fi rst” study (26), which 
systematically includes analysis of the paternal (in lieu of the 
fetal) genome to more accurately interpret the epidemiologi-
cal association between maternal thrombophilia and fetal loss. 
Third, it establishes a novel and unique animal model of fetal 
loss associated with maternal inherited thrombophilia. Us-
ing this animal model, we have identifi ed the Par4 receptor 
on maternal platelets as a key component of the pathogenic 
mechanism underlying fetal loss in FvL mice and have deter-
mined that, at least in mice, fetal loss occurs in the absence 
of overt thrombosis. The relevance of our observations for 
human FvL carriers remains to be determined.
Based on placental pathology, the pathogenesis of FvL-
associated fetal loss in mice appears distinct from the com-
plement-driven mechanism operating in fetal loss induced 
by antiphospholipid antibodies (27). Consistent with this 
notion, platelet depletion did not ameliorate fetal loss in 
the antiphospholipid model, and anti-C5 antibody treat-
ment was insuffi  cient to rescue fetal loss in the FvL model 
(unpublished data).
In striking contrast to fetal loss caused by reduced func-
tion or expression of Thbd or Procr on trophoblast cells 
in FvL mothers, the combination of the same risk factors 
does not cause acute thrombosis in the systemic vasculature. 
The reverse is true for Tfpi, where lethal thrombosis ensues 
when heterozygous Tfpi defi ciency is combined with FvL 
homozygosity in the same animal (18) but is inconsequen-
tial with respect to pregnancy outcome. The absence of a 
measurable consequence of embryonic Tfpi heterozygosity 
on pregnancy outcome in FvL mothers may refl ect a sub-
stantial contribution of maternally derived plasma Tfpi in 
local hemostasis at the fetomaternal interface. Collectively, 
these observations demonstrate a marked discrepancy of con-
sequences (i.e., thrombosis vs. pregnancy loss) triggered by 
the interaction of thrombosis risk factors in diff erent vascular 
beds and suggest that the eff ect of a given risk modifi er on 
venous or arterial thrombosis is not necessarily predictive of 
pregnancy outcome.
The placental abnormalities of embryos with reduced 
Thbd activity carried by FvL mothers and those associated 
with Thbd-null embryos (15) share characteristic features 
suggestive of a common underlying pathogenic mechanism. 
Both occur in the absence of overt thrombosis. Embryos 
with reduced Thbd activity in FvL mothers can be rescued 
by platelet depletion at E7.5 but not at E9.5, indicating that 
the pathogenic insult has already occurred by E9.5. Growth 
retardation of Thbd-null embryos is observed as early as E8.5, 
suggesting a similar time of pathogenic insult. In both cases, 
placental morphogenesis is disrupted at the time of labyrinth 
layer formation. The combined results from the analysis of 
fetal loss in these two models suggest that the expression of 
tissue factor on placental trophoblast cells provides a constitu-
tive procoagulant stimulus in the placental vascular bed (15, 19). 
The protein C anticoagulant pathway sustained by expression 
of Thbd and Procr on trophoblast cells appears to be neces-
sary to suppress this stimulus. Localized disruption of this 
pathway at the fetomaternal interface—either caused by the 
complete lack of Thbd or Procr from trophoblast cells or a 
combination of fetal and maternal risk factors—permits am-
plifi cation of the coagulation reaction and formation of acti-
vated clotting factors, including thrombin. We fi nd that 
platelets and Par4 are critical mediators of placental failure. 
The impairment of placental growth and morphogenesis is 
therefore caused by a process similar to the initial tissue factor– 
and thrombin-dependent stages of arterial thrombosis, likely 
involving platelet activation, but does not require thrombotic 
occlusion. Possible explanations for the lack of occlusive 
thrombi in the setting of an active coagulation cascade in-
clude inhibition of ADP-driven platelet aggregation caused 
by abundant expression of ecto-ATPDase/CD39 on the tro-
phoblast cell surface (19).
The nature of the mechanism by which activation of ma-
ternal platelets causes pregnancy failure is unknown, but the 
possibility that platelet-released factors negatively infl uence 
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placental development or function is an obvious candidate. 
Peptide mediators with (anti)angiogenic activity have been 
suggested to alter trophoblast function and contribute to 
the etiology of pregnancy disorders such as preeclampsia 
(28–30). Of note, platelets have been shown to adhere to 
endovascular trophoblasts within the lumen of spiral arter-
ies in normal pregnancy (30), indicating that the recruitment 
of platelets to the fetomaternal interface is a physiological 
process that links platelet function to the regulation of pla-
cental development.
It is noteworthy that fetal loss in FvL animals occurs in the 
absence of overt thrombosis in the mother’s systemic vascu-
lature and is caused by a highly localized defect precipitated 
by the fetal genotype, which aff ects individual placental beds. 
Local dysregulation of the protein C anticoagulant pathway 
at the fetomaternal interface alone (Thbd−/− embryos) is 
also suffi  cient to cause fetal loss in a mother with near-
normal hemostatic function (Thbd+/− mothers) (15). Com-
plete disruption of the protein C pathway (≤3% of protein 
C), on the other hand, is accompanied by active thrombotic 
disease, consumptive coagulopathy, and a severe proinfl am-
matory phenotype (31). These animals suff er fetal genotype-
independent early pregnancy loss (E6.5) with a markedly 
diff erent disease etiology caused by the pronounced secondary 
eff ects of acute protein C defi ciency in the mother. Increas-
ing maternal protein C to 18% of wild-type levels overcomes 
systemic thrombosis and infl ammation and restores normal 
pregnancies (31).
In summary, we have presented animal models of pla-
cental malfunction and fetal loss secondary to inherited de-
fects in the protein C anticoagulant pathway, including a 
clinically relevant gene defect (FvL) in the mother. The loss 
of ThbdProPro embryos in FvL mothers correlates with the 
early fetal loss observed in women with the Leiden muta-
tion. We also observed a partial loss of embryos with a hetero-
zygous defect in Thbd function (ThbdPro+) later in pregnancy 
(around E12.5, correlating with Leiden-associated late fetal 
loss in women) that we did not characterize further in 
this study. The early fetal loss in FvL mice is preceded by 
disrupted placental growth and morphogenesis during de-
velopmental events that lead to the formation of a func-
tional labyrinth and is mediated through a platelet and Par4 
receptor–driven mechanism but does not involve forma-
tion of occlusive thrombi in the placenta. The described 
animal model of thrombophilia-associated fetal loss pro-
vides an opportunity to test the effi  cacy of antithrombotic 
treatments and, possibly, of antiplatelet treatments targeting 
the recruitment and activation of platelets in the placental 
vascular bed.
MATERIALS AND METHODS
Mice. Animal experiments were conducted according to standards and pro-
cedures approved by the Animal Care and Use Committee of the Medical 
College of Wisconsin. Fv Leiden (provided by D. Ginsburg, University of 
Michigan, Ann Arbor, MI), Thbd Pro, Procr∂/∂ (provided by F. Castellino, 
University of Notre Dame, Notre Dame, IN), and TFPI+/− (provided by 
G. Broze, Washington University School of Medicine, Saint Louis, MO) mice 
have been previously described (13, 17, 20, 32). These mice were main-
tained on C57BL/6 genetic background.
Histology. Embryonic development was assessed from dpc, assuming mid-
day of plug as 0.5 dpc, and as previously described (15). Dissections were 
performed, and pictures of embryos were taken under a microscope (SMZ-
U; Nikon) equipped with a color camera (SPOT Insight; Diagnostic Instru-
ments) and SPOT software (version 3.2.4; Diagnostic Instruments). 7-μm 
serial sections of formalin-fi xed (Sigma-Aldrich), paraffi  n-embedded tissues 
were stained with hematoxylin and eosin for general morphology, identifi -
cation of thrombi, and morphometric analysis. Thrombi were validated by 
immunostaining with antibodies that recognize fi brinogen (DakoCytoma-
tion) and p-selectin (Santa Cruz Biotechnology, Inc.). Immunostaining with 
antibodies against cytokeratin (DakoCytomation) was done after antigen re-
trieval with 40 μg/ml proteinase K in 10 mM Tris, pH 7.5, at 37°C for 
30 min. ImageJ software (version 1.36b; National Institutes of Health) was 
used for morphometric analysis. Sizes of the decidua and placenta were mea-
sured on every 30th section, and the totals were used to arrive at decidua/
placenta ratio.
Perfusion studies and TAT and D-dimer measurements. Placental 
perfusion was examined by injecting pregnant females with 100 μl of 25 
mg/ml FITC-labeled dextran (mol wt 200 × 104; Sigma-Aldrich) via the tail 
vein at 9.5 dpc. After 15 min, the uteroplacental units were dissected under 
a microscope (SteREO Discovery.V12 PentaFluar S; Carl Zeiss Micro-
Imaging, Inc.) equipped with a GFP fi lter cube (excitation, BP470/40; emission, 
BP525/50) and a camera (Axiocam MRc5; Carl Zeiss MicroImaging, Inc.). 
The fetal aspect of the placenta was photographed using Axiovision software 
(version 4.5; Carl Zeiss MicroImaging, Inc.). The uteroplacental units were 
embedded in tissue-freezing medium (Triangle Biomedical Sciences) and 
fl ash frozen in a dry ice–ethanol bath. Serial sections of the frozen units were 
examined and photographed under a microscope (Eclipse TE200; Nikon) 
equipped with a camera (Photometrics CoolSNAP ES; Roper Scientifi c, 
Inc.) using Metamorph software (version 6.2r6; Universal Imaging Corp.). 
D-dimer and TAT levels were measured as previously described (33).
Platelet depletions. For platelet depletion, a mixture of anti-GPIbα rat 
monoclonal antibodies (34) or polyclonal nonimmune IgG (control; R300 
or C301, Emfret Analytics) was injected via the tail vein at 4 μg/g body 
weight. Anti-GPIbα antibodies depleted 95% of the platelets within 1 h, as 
counted manually and with an automated cell counter (ABX Diagnostics). 
Injections were repeated on the fourth day.
Statistical analysis. The signifi cance of survival diff erences between groups 
was determined using the χ2 analysis. The Student’s t test (two-tailed with 
unequal variance) was used for all other statistical analysis. P < 0.05 was 
considered signifi cant.
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